Concord Drugs Ltd

Net profit of Concord Drugs declined 4.35% to Rs 0.22 crore in the quarter ended December 2025 as against Rs 0.23 crore during the previous quarter ended December 2024. Sales rose 57.13% to Rs 16.97 crore in the quarter ended December 2025 as against Rs 10.80 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales16.9710.80 57 OPM %5.5412.87 - PBDT0.600.90 -33 PBT0.300.53 -43 NP0.220.23 -4 Powered by Capital Market - Live

Concord Drugs will hold a meeting of the Board of Directors of the Company on 14 February 2026.Powered by Capital Market - Live

The key domestic indices traded with minor cuts in mid-afternoon trade amid continued foreign institutional investor (FII) selling. Trading activity remained range-bound in the absence of strong domestic triggers and ahead of the year-end holiday period. The Nifty traded below the 25,950 mark. PSU Bank shares witnessed buying demand for second straight session. At 14:25 IST, the barometer index, the S&P BSE Sensex declined 3.75 points or 0.10% to 84,608.82. The Nifty 50 index lost 13.70 points or 0.05% to 25,928.40. In the broader market, the S&P BSE Mid-Cap index fell 0.07% and the S&P BSE Small-Cap index shed 0.10%. The market breadth was negative. On the BSE, 1,828 shares rose and 2,263 shares fell. A total of 189 shares were unchanged. Buzzing Index: The Nifty PSU bank index jumped 1.46% to 8,412.90. The index rose 1.51% in the two trading sessions. Indian Bank (up 2.67%), Bank of Maharashtra (up 2.65%), Canara Bank (up 1.56%), Indian Overseas Bank (up 1.48%), Union Bank of India (up 1.23%), Bank of Baroda (up 1.2%), Punjab National Bank (up 1.16%), Bank of India (up 1.04%), UCO Bank (up 1.02%) and State Bank of India (up 0.85%) surged. Numbers to Track: The yield on India's 10-year benchmark federal paper rose 0.03% to 6.597 as compared with the previous close of 6.595. In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 89.8175 compared with its close of 89.9825 during the previous trading session. MCX Gold futures for 5 February 2026 settlement advanced 0.64% to Rs 135,829. The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.01% to 98.02. The United States 10-year bond yield rose 0.07% to 4.120. In the commodities market, Brent crude for February 2025 settlement advanced 15 cents or 0.24% to $62.09 a barrel. Stocks in Spotlight: Concord Drugs rallied 3.48% after the company announced that it has secured an order worth Rs 14.71 crore for the supply of various pharmaceutical products. Waaree Renewable Technologies rose 0.53%. The company has secured a domestic order from India's largest manufacturers of pig iron, castings, and seamless tubes to develop a 35 MWp ground-mount solar power project on a turnkey basis, including operation & maintenance (O&M).Powered by Capital Market - Live

The project involves supplying various government healthcare agencies, including TNMSC (six purchase orders), DGHS via Government Medical Stores Depots, TNMSC under the Mudhalvar Marundhagam Scheme (32 purchase orders), TGMSIDC, and other entities, with execution scheduled over the next 45 to 60 days. The company's consolidated net profit surged 375% to Rs 0.19 crore on a 16.8% drop in revenue to Rs 10.28 crore in Q2 FY26 over Q2 FY25.Powered by Capital Market - Live

Net profit of Concord Drugs rose 375.00% to Rs 0.19 crore in the quarter ended September 2025 as against Rs 0.04 crore during the previous quarter ended September 2024. Sales declined 16.83% to Rs 10.28 crore in the quarter ended September 2025 as against Rs 12.36 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales10.2812.36 -17 OPM %10.707.12 - PBDT0.610.41 49 PBT0.270.07 286 NP0.190.04 375 Powered by Capital Market - Live

Concord Drugs will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live

Concord Drugs announced that the Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live

Net profit of Concord Drugs rose 300.00% to Rs 0.12 crore in the quarter ended June 2025 as against Rs 0.03 crore during the previous quarter ended June 2024. Sales rose 16.42% to Rs 13.61 crore in the quarter ended June 2025 as against Rs 11.69 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales13.6111.69 16 OPM %7.497.10 - PBDT0.530.38 39 PBT0.160.04 300 NP0.120.03 300 Powered by Capital Market - Live

Concord Drugs will hold a meeting of the Board of Directors of the Company on 8 August 2025.Powered by Capital Market - Live

Concord Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 31 July 2025.Powered by Capital Market - Live